Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol

British Journal of Pharmacology

Volumn 171, Issue 17, 2014, Pages 4062-4072

  Obiorah, I E ^a   Jordan, V C ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

bisphenol; breast cancer; Oestrogen induced apoptosis

Indexed keywords

1,1,2 TRIPHENYLETHYLENE; ANTINEOPLASTIC AGENT; BIPHENYLDIOL; CELL DNA; ESTRADIOL; ESTROGEN RECEPTOR; ETHYLENE DERIVATIVE; MESSENGER RNA; UNCLASSIFIED DRUG; 1,1-BIS(4-HYDROXYPHENYL)-2-PHENYLBUT-1-ENE; APOPTOSIS REGULATORY PROTEIN; ESTROGEN; STILBENE DERIVATIVE;

APOPTOSIS; APOPTOTIC GENE; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL CYCLE GENE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DETERMINATION; ENDOPLASMIC RETICULUM STRESS; FLOW CYTOMETRY; GENE; GENE ACTIVATION; GENE CONTROL; HUMAN; HUMAN CELL; INFLAMMATORY STRESS RESPONSE GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; BREAST NEOPLASMS; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; MCF-7 CELLS; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84905974776     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12762     Document Type: Article

References (41)

1. Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, et-al. (1990). A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J 9: 1897-1906.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
3. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, et-al. (2012). Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 13: 476-486.
4. Ariazi E, Cunliffe H, Lewis-Wambi JS, Slifker M, Willis A, Ramos P, et-al. (2011). Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A 108: 18879-18886.
5. Bian Z-M, Elner SG, Elner VM, (2009). Dual involvement of caspase-4 in inflammatory and ER stress-induced apoptotic responses in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 50: 6006-6014.
6. Bourgoin-Voillard S, Gallo D, Laïos I, Cleeren A, Bali LE, Jacquot Y, et-al. (2010). Capacity of type 1 and 11 ligands to confer to estrogen receptor alpha an appropriate conformation for the recruitment of coactivators containing a LxxLL motif-relationship with the regulation of receptor level and ERE-dependent transcription in MCF-7 cells. Biochem Pharmacol 79: 746-757.
7. Ellis M, Gao F, Dehdashti F, Jeffe D, Marcom P, Carey L, et-al. (2009). Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 302: 774-780.
8. Fan P, Griffith OL, Agboke FA, Anur P, Zou X, McDaniel RE, et-al. (2013). c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. Cancer Res 73: 4510-4520.
9. Haddow A, (1970). David A Karnosky memorial lecture: thoughts on chemical therapy. Cancer Res 26: 737-754.
10. Haddow A, Watkinson JM, Patterson E, (1944). Influence of synthetic oestrogens upon advanced malignant disease. BMJ 2: 393-398.
11. Hitomi J, Katayama T, Eguchi Y, Kudo T, Taniguchi M, Koyama Y, et-al. (2004). Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Aβ-induced cell death. J Cell Biol 165: 347-356.
12. Hu ZZ, Kagan BL, Ariazi EA, Rosenthal DS, Zhang L, Li JV, et-al. (2011). Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells. PLoS ONE 6: e20410.
13. Jordan VC, (2004). Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5: 207-213.
14. Jordan VC, (2008). The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer-survival or death? J Clin Oncol 26: 3073-3082.
15. Jordan VC, Lieberman ME, (1984). Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure. Mol Pharmacol 26: 279-285.
16. Jordan VC, Lieberman ME, Cormier E, Koch R, Bagley JR, Ruenitz PC, (1984). Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro. Mol Pharmacol 26: 272-278.
17. Jordan VC, Koch R, Mittal S, Schneider MR, (1986). Oestrogenic and antioestrogenic actions in a series of triphenylbut-1-enes: modulation of prolactin synthesis in vitro. Br J Pharmacol 87: 217-223.
18. Jordan VC, Schafer JM, Levenson AS, Liu H, Pease KM, Simons LA, et-al. (2001). Molecular classification of estrogens. Cancer Res 61: 6619-6623.
19. Jordan VC, Obiorah I, Fan P, Kim HR, Ariazi E, Cunliffe H, et-al. (2011). The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. Breast Suppl 3: S1-S11.
20. Kim S-J, Zhang Z, Hitomi E, Lee Y-C, Mukherjee AB, (2006). Endoplasmic reticulum stress-induced caspase-4 activation mediates apoptosis and neurodegeneration in INCL. Hum Mol Genet 15: 1826-1834.
21. Lahusen T, Henke RT, Kagan BL, Wellstein A, Riegel AT, (2009). The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat 116: 225-237.
22. Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, et-al. (2005a). Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 97: 1746-1759.
23. Lewis JS, Osipo C, Meeke K, Jordan VC, (2005b). Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 94: 131-141.
24. Lewis-Wambi J, Jordan VC, (2009). Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 11: 206.
25. Lieberman ME, Gorski J, Jordan VC, (1983). An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J Biol Chem 258: 4741-4745.
26. List H-J, Lauritsen KJ, Reiter R, Powers C, Wellstein A, Riegel AT, (2001). Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem 276: 23763-23768.
27. Maximov P, Sengupta S, Lewis-Wambi JS, Kim HR, Curpan RF, Jordan VC, (2011). The conformation of the estrogen receptor directs estrogen-induced apoptosis in breast cancer: a hypothesis. Horm Mol Biol Clin Investig 5: 27-34.
28. Maximov PY, Myers CB, Curpan RF, Lewis-Wambi JS, Jordan VC, (2010). Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen. J Med Chem 53: 3273-3283.
29. Obiorah I, Jordan VC, (2013). 2012 NAMS/PFIZER-Wulf H. Utian endowed lecture. The scientific rationale for a delay after menopause in the use of conjugated equine estrogens in postmenopausal women that causes a reduction in breast cancer incidence and mortality. Menopause 20: 372-382.
30. Obiorah I, Sengupta S, Curpan R, Jordan VC, (2014a). Defining the conformation of the estrogen receptor complex that controls estrogen induced apoptosis in breast cancer. Mol Pharmacol 85: 789-799.
31. Obiorah I, Surojeet S, Fan P, Jordan VC, (2014b). Delayed triggering of estrogen induced apoptosis that contrasts with rapid paclitaxel induced breast cancer cell death. Br J Cancer 110: 1488-1496.
32. Oyadomari S, Mori M, (2003). Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11: 381-389.
33. Robson JM, Schonberg A, (1937). Oestrous reactions, including mating, produced by triphenylethylene. Nature 140: 196.
34. Ron D, Habener JF, (1992). CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 6: 439-453.
35. Sengupta S, Sharma CG, Jordan VC, (2010). Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Horm Mol Biol Clin Investig 2: 235-243.
36. Sengupta S, Obiorah I, Maximov PY, Curpan R, Jordan VC, (2013). Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol 169: 167-178.
37. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, et-al. (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95: 927-937.
38. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, et-al. (2001). Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 93: 1714-1723.
39. Styner M, Meyer MB, Galior K, Case N, Xie Z, Sen B, et-al. (2012). Mechanical strain downregulates C/EBPbeta in MSC and decreases endoplasmic reticulum stress. PLoS ONE 7: 12.
40. Wolf DM, Jordan VC, (1993). A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res 127: 23-33.
41. Yao K, Lee E, Bentrem D, England G, Schafer J, O'Regan R, et-al. (2000). Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6: 2028-2036.